Most Read Articles
Pearl Toh, 4 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.

Neoadjuvant FOLFIRINOX, chemoradiotherapy improve pancreatic cancer surgery outcomes

08 Aug 2018

Treatment with a neoadjuvant regimen containing fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) followed by individualized chemoradiotherapy for borderline resectable pancreatic cancer leads to high margin-negative (R0) resection rate, which translates to longer survival, according to the results of a single-arm phase II trial.

The trial enrolled 48 treatment-naïve patients (median age 62 years; 56.3 percent male) who had ECOG performance status of 1–0 and adequate haematologic, renal and hepatic function. Forty-three received eight cycles of FOLFIRINOX. Those who showed resolution of vascular involvement underwent short-course chemoradiotherapy (5 Gy) with capecitabine, while those with persistent vascular involvement underwent long-course treatment with fluorouracil or capecitabine.

Of the patients who planned to receive eight preoperative cycles of chemotherapy, 34 (79 percent) completed treatment. Twenty-seven (56 percent) had short-course chemoradiotherapy, while 17 (35 percent) received long course. Nearly all the 32 patients who underwent resection achieved R0 (97 percent).

In the entire cohort, median progression-free survival (PFS) was 14.7 months (95 percent CI, 10.5–not reached) while median overall survival was 37.7 months (19.4–not reached). The respective 2-year PFS and OS were 43 percent and 56 percent.

In the group of patients who underwent resection, median PFS was 48.6 months while median OS had not been reached. The corresponding 2-year PFS and OS were 55 percent and 72 percent.

Neoadjuvant FOLFIRINOX followed by chemoradiotherapy had a favourable toxicity profile, with no single grade 3 toxicity exceeding 10 percent and no toxic effect resulting in death.

The median follow-up for the analysis was 18.0 months for the 30 patients still alive at study completion.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.